Bottle of lies: How poor FDA oversight & fraud in generic drug industry threaten patients’ health

In her new explosive book “Bottle of Lies: The Inside Story of the Generic Drug Boom,” investigative journalist Katherine Eban works with two industry whistleblowers to expose how some manufacturers are cutting corners at the cost of quality and safety.

403
SOURCEDemocracy Now!

Generic drugs amount to 90% of all prescriptions filled in the U.S., most of them made in plants in India and China. Generic drugs can be more affordable, but in her new explosive book “Bottle of Lies: The Inside Story of the Generic Drug Boom,” investigative journalist Katherine Eban works with two industry whistleblowers to expose how some manufacturers are cutting corners at the cost of quality and safety. This comes as the U.S. Food and Drug Administration just issued its own update on the state of pharmaceutical quality that found the drug quality of factories in India and China scored below the world average. FDA officials say that’s because more robust inspections have uncovered problems and that “the quality of the drug supply has never been higher.”

Guests

  • Katherine Ebanauthor of Bottle of Lies: The Inside Story of the Generic Drug Boom, which has just been published. She is also the author of a previous book on the pharmaceutical industry titled Dangerous Doses: A True Story of Cops, Counterfeiters, and the Contamination of America’s Drug Supply. Eban is a contributor to Fortune magazine and was previously a staff writer for The New York Times and The New York Observer.

FALL FUNDRAISER

If you liked this article, please donate $5 to keep NationofChange online through November.

Fall 2019

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Donation Total: $5.00 One Time

COMMENTS